BFRI Biofrontera
- 1.5800
- +0.0400+2.60%
- 1.5800
- 0.00000.00%
Biofrontera News
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results
Biofrontera Files to Sell 11.31M Shares for Holders
Biofrontera Announces Achievement of Two Milestones Associated With Series B-3 Convertible Preferred Stock Warrants
WOBURN MA / ACCESSWIRE / May 3, 2024 / WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. , a biopharmaceutical company specializing in the commercialization of dermatological
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stoc
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce
Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript
Analysts' Top Healthcare Picks: Biofrontera (BFRI), Alpine Immune Sciences (ALPN)
Q4 2023 Biofrontera Inc Earnings Call
Earnings Call Summary | Biofrontera(BFRI.US) Q4 2023 Earnings Conference
The following is a summary of the Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript:Financial Performance:Q4 and total 2023 revenue was $10.6 million and $34.1 million respectively, an increase
Biofrontera GAAP EPS of $1.65 Beats by $2.79, Revenue of $10.6M Misses by $1.21M
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company speci
VERI, STI and VERB Among Mid-day Movers
Geron, Graphite Bio, Immuneering Among Healthcare Movers
Earnings Scheduled For March 15, 2024
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. • NeoGenomics (NASDAQ:NEO) is likely to report qua
Biofrontera's Earnings Outlook
Biofrontera (NASDAQ:BFRI) is set to give its latest quarterly earnings report on Friday, 2024-03-15. Here's what investors need to know before the announcement.Analysts estimate that Biofrontera will
Biofrontera Files Prospectus for Potential Secondary Stock Offerings
Biofrontera (BFRI) filed a prospectus for resale of about 9.3 million shares from time to time by selling shareholders. The selling shareholders include ITF Rosalind Master Fund, Lytton-Kambara Founda
Biofrontera Files to Sell 9.31M Shares of Common Stock for Holders
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will rep
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAinos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. The market value of their outstanding shares is at $10.4 million. Talphera (NASDAQ:TLPH) stoc
Analysis
Price Target
No Data
